A multicentre, two-part, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, tolerability and pharmacokinetics of the iNOS inhibitor GW274150 administered up to 120mg daily for 12 weeks in the prophylactic treatment of migraine.

Trial Profile

A multicentre, two-part, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, tolerability and pharmacokinetics of the iNOS inhibitor GW274150 administered up to 120mg daily for 12 weeks in the prophylactic treatment of migraine.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2015

At a glance

  • Drugs GW 274150 (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Oct 2008 Actual start date changed from Jan 2007 to Oct 2005 as reported by ClinicalTrials.gov
    • 09 Jun 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov
    • 01 Jun 2007 Status change from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top